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Section 1: Introduction  
Hemoglobin biology and the functional importance of the oxyhemoglobin dissociation curve 
Hemoglobin is crucial to the transportation of oxygen within the circulation of all 
vertebrates, and some invertebrates. The evolution of globin genes over time has led to the 
complex structure we are familiar with in human blood today. Hemoglobin is a 
heterotetramer consisting of two alpha and two beta polypeptide chains, each with a 
central heme group comprised of an iron ion and a porphyrin ring.(1, 2) The iron-
containing heme group on each of the four protein subunits permits binding of one oxygen 
molecule. Oxygen is bound to hemoglobin in regions of high partial pressure of oxygen 
(pO2), such as the lungs, and 
then released into the tissues, 
where pO2 is low due to cellular 
oxygen consumption. The pO2 
varies between normal tissues 
and this range can be 
considered “physioxia”. (3) The 
affinity of hemoglobin for 
oxygen in relation to pO2 is 
described by the oxygen-hemoglobin dissociation curve (ODC) illustrated in Figure 1. One 
of the unique features of hemoglobin is that it exhibits molecular cooperativity, responsible 
for the sigmoid shape of the ODC, that enables hemoglobin to alternate between two 
structures; the relaxed (oxyhemoglobin) and tense (deoxyhemoglobin) states, the latter 
demonstrating lower affinity for oxygen. This allows flexibility in terms of how much 
oxygen hemoglobin can bind, ensuring that the functional groups attain maximal affinity 
for oxygen. When a monomer of hemoglobin binds a molecule of oxygen a conformational 
change is induced in the three neighboring monomers, increasing their affinity for oxygen. 
Cooperativity also enables flexibility in how much oxygen is released to tissues. The p50 of 
hemoglobin is the pO2 at which hemoglobin is 50% saturated with oxygen (50% 
oxyhemoglobin, 50% deoxyhemoglobin), and quantifies the affinity of hemoglobin for 
permitting comparison of the relative affinities of different hemoglobins or conditions. The 
normal p50 range in an adult is 24–28 mmHg (3.2-3.7 kPa), however, the value varies 
throughout the body depending on the local environment (for example temperature and 
pH).  The standard p50 (P50s) is an idealized value calculated from the measured pO2 when 
the temperature of blood is 37.0 oC, partial pressure of carbon dioxide (pCO2) is 40 mmHg, 
blood pH is 7.40 and carboxyhemoglobin (COHb) is < 2%. In contrast, the in vivo p50 
reflects the oxygen tension at which hemoglobin is 50% saturated at the pH, pCO2, 
temperature and COHb level of the subject.  
 To accurately determine the p50, the ODC must be constructed or a Hill plot 
created.(4) In clinical practice, arterial blood gas machines estimate the p50 using a single-
point measurement and hemoglobin-oxygen saturation.(5) Most devices require the 
oxyhemoglobin saturation to lie on the straight section of the ODC, therefore desaturated, 
venous blood should be used. Alternatively, the Siggaard-Anderson oxygen status 
algorithm(6), incorporating the Tahn equation, is the single-point method that can most 
accurately calculate the p50 up to an oxygen-hemoglobin saturation of 97%. 
 
Principles of oxygen transport and the physiology of oxygen delivery 
Uptake of oxygen into the blood from the alveolus is determined by the pO2 gradient 
across the alveolar membrane, the properties of the membrane, and the flow of blood 
through the pulmonary circulation, alongside physical properties the hemoglobin molecule. 
Oxygen has a low solubility in plasma (0.225ml per kPa of oxygen per liter of blood), 
therefore without hemoglobin, the circulation would not be able to transport sufficient 
oxygen to organs. The actual volume of oxygen that can bind to hemoglobin in vivo remains 
controversial; the theoretical maximum volume of oxygen that can be carried by 
hemoglobin is 1.39 ml of O2/gram of Hb(7); however, this figure does not account for 
variant species of hemoglobin that are unable to bind oxygen, such as carboxyhemoglobin 
and methemoglobin. Human studies have demonstrated that a value of 1.34 ml of O2/gram 
of Hb might be more realistic.(8)  
Table 1 Relevant equations 
 
𝐶𝑎𝑂2 = ([𝐻𝑏] ∗ 𝐻 ∗ 𝑆𝑎𝑂2) + (𝑃𝑎𝑂2 ∗ 𝑎𝑂2) and 𝐶𝑣𝑂2 = ([𝐻𝑏] ∗ 𝐻 ∗ 𝑆𝑣𝑂2) + (𝑃𝑣𝑂2 ∗ 𝑎𝑂2) 
?̇?𝑂2 = ?̇? ∗ 𝐶𝑎𝑂2  
𝐴𝑉𝑂2𝑑𝑖𝑓𝑓 = 𝐶𝑎𝑂2 − 𝐶𝑣𝑂2 ≈ [𝐻𝑏] ∗ 𝐻 ∗ (𝑆𝑎𝑂2 − 𝑆𝑣𝑂2) 
?̇?𝑂2 =  ?̇? ∗ 𝐴𝑉𝑂2𝑑𝑖𝑓𝑓 






[Hb] = hemoglobin concentration (g/dL) 
H = Hufner’s Constant (1.34 mL O2/g Hb) 
SaO2 or SvO2 = arterial or venous oxygen saturation percent 
𝑎𝑂2= solubility of oxygen in water = 0.0031 mL O2/mmHg/dL 
PaO2 or PvO2 = arterial or venous oxygen tension (mmHg) 
?̇? = cardiac output (L/min) 
 The amount of oxygen carried within arterial blood is referred to as arterial oxygen 
content (CaO2) (Table 1). Approximately 98% of circulating oxygen is carried bound to 
hemoglobin whilst the remaining 2% is dissolved in plasma.(9) Systemic oxygen delivery 
(DO2) is the total volume of oxygen, per minute, transported to the tissues from the lungs 
via the circulation. Oxygen delivery is a product of cardiac output and CaO2 (Table 1). In a 
healthy male adult of 70kg weight, systemic oxygen delivery is approximately 1000 
ml/l/min (the product of 200ml/l CaO2 and 5 l/min cardiac output). 
  At the tissue level, oxygen supply and demand is dependent on a number of factors 
including diffusion limitation of oxygen from the microcirculation to mitochondria and an 
array of variables impacting on local tissue oxygen consumption (including sedation, tissue 
edema, hypothermia/cooling and metabolic rate increased with seizures, burns or sepsis). 
Likewise, oxygen delivery can be optimized by the manipulation of cardiac output, 
hemoglobin and SaO2. However, it is the affinity of hemoglobin for oxygen, its modulation 
and its potential impact on capillary oxygen supply that is the focus of this article.  
 
Physiological modulation of the p50 and its relevance to peripheral oxygen delivery  
 The p50 is a measure of the affinity of hemoglobin for oxygen that determines the 
release of oxygen from the microcirculation into the tissues. An increased p50 (equivalent 
to a rightwards shift of the ODC in Figure 1) is indicative of a decreased hemoglobin-oxygen 
binding affinity promoting the release of oxygen to the tissues. Such an increase in p50 can 
be considered advantageous within tissues that have a high metabolic rate, and therefore 
high oxygen consumption, such as active skeletal muscle.  
 The relevance of an increased p50 to peripheral oxygen delivery is illustrated by the 
physiological responses to acute altitude acclimation and anemia, both of which result in a 
compensatory increase in production of 2,3-DPG in an effort to restore the tissue 
oxygenation lost with hypoxemia or anemia. With regards to the physiological process of 
acclimatization to altitude, a study to assess p50 during a simulated ascent of Mount 
Everest, Operation Everest II,(10) demonstrated an increase in p50 at a simulated altitude 
of 29,029 ft; most likely as a result of the hypoxia-induced increase in 2,3-DPG(11).  
 Conversely, a leftward shift of the oxygen dissociation curve (a decrease in p50), 
results in increased hemoglobin-oxygen affinity and hence decreased oxygen delivery to 
the peripheral tissues. Tissue oxygen extraction becomes impaired, hence tissue hypoxia 
may exist despite a normal PaO2, as reflected in the compensatory erythrocytosis seen in 
high affinity haemoglobin variants.(12) Fetal hemoglobin (HbF) has a lower p50 than adult 
hemoglobin (approximately 19 mmHg), an adaptation to the hypoxic conditions in utero 
that promotes superior oxygen affinity, which in turn facilitates oxygen extraction from 
maternal hemoglobin across the placental membrane. Likewise, methemoglobin (MetHb) 
and carboxyhemoglobin (COHb) have increased affinity of hemoglobin for oxygen, and will 
decrease the apparent p50 even if the natural hemoglobin p50 remains the same. 
Myoglobin has a p50 of approximately 3 mmHg, an extraordinarily high affinity for oxygen, 
essential for myoglobin’s role in storing, loading and unloading oxygen in the PO2 range of 
active skeletal muscle.  
 
 
Section 2:  
Haemoglobin variants with an altered p50 
In 1961, Reissmann et al described a case of familial cyanosis secondary to a 
hemoglobin variant with abnormally low oxygen affinity.(13) This variant (hemoglobin 
Kansas) was first identified in a 14-year old with cyanosis since birth. He was entirely 
asymptomatic aside some periods of weakness after severe exertion, but had markedly 
diminished oxygen saturation in the presence of normal oxygen partial pressures. An in 
vivo ODC demonstrated a marked shift to the right with an increase in p50 to ~70mmHg.  
Similarly, Avellan-Hietanen et al. reported a case of a patient presenting with 
pneumonia, but with an unexpectedly low SpO2. The low SpO2 persisted after recovery, 
despite lack of hypoxic manifestations and normal exercise tolerance, and a rare point 
mutation in the alpha-chain-coding gene known as hemoglobin Titusville was 
discovered.(14) This point mutation resulted in a lower oxygen affinity (p50 ~40mmHg), 
hence the SpO2 of arterial blood appeared low while the pO2 was normal.  
Conversely, high oxygen affinity hemoglobins are responsible for around 100 rare 
and heterogenous autosomal dominant genetic diseases, resulting in decreased tissue 
oxygen delivery and erythrocytosis. The diagnosis is based on the identification of a 
decreased p50 on arterial blood gas analysis and their characterisation by capillary 
electrophoresis. Many of the mutations associated with a high affinity phenotype map to 
the α1β2 hemoglobin subunit, preventing the transition of the Hb molecule to the low 
oxygen affinity state (T or tense) and hence inability to release bound oxygen 
molecules.(15) 
Clinical relevance of p50 
  Of particular note,is the observation that the p50 of transfused blood is un-
physiologically low; (16) the potential deleterious effects of that is illustrated in Figure 2. 
The blue ODC represents 21 day 
old PRBCs with an SaO2 of 99% 
and the lowest achievable SvO2 is 
54%, assuming an arterial pO2 of 
100mmHg and the venous pO2 in 
exercising muscle of 20mmHg.(17) 
If the p50 of this unit is 
allosterically modified by 
increasing 2,3DPG levels to 150% normal (the right-shift, red ODC), the SaO2 is 95% and 
the lowest achievable SvO2 is 12%. The A-V difference, therefore, is 83% for high p50 
blood and 45% for low p50 blood, a huge difference. Considering that VO2 is a product of  
cardiac output and (SaO2-SvO2), each unit of high p50 gives almost twice as much VO2 
increase as a low p50 unit, assuming the cardiac output remains constant. Transfusing 
blood with an increased oxygen affinity, such that it is less likely to off-load oxygen in the 
tissues, seems counter-intuitive. However, excessively elevating the p50 into the range 
seen with the Hb mutants, Titusville or, especially, Kansas, may worsen hypoxemia in the 
setting of acute lung injury. Several questions remain unanswered regarding the optimal 
p50 target. Nevertheless, the manipulation of oxygen affinity and hence development of a 
future therapeutic target to increases VO2 ideally with lower cardiac output requirements 
or lower transfusion thresholds, has exciting potential. 
 
Relationship between p50 and VO2 
 The major determinant of exercise capacity is the amount of oxygen available to 
exercising muscles, a function of 
DO2 and the extraction ratio that 
determines achievable VO2. The 
upper limit of oxygen utilization 
during exercise (VO2max) is 
defined as the point at which 
progressively increasing work rate fails to elicit further increases in oxygen uptake. 
VO2max coincides with the point of physical exhaustion(18) and is the most commonly 
used, and highly reproducible,(19, 20) measure of aerobic fitness. While used as a measure 
of fitness, VO2 max also reflects the maximum achievable VO2 in the setting of acute illness 
and offers insight into how we can manipulate this important parameter to optimize 
hemodynamics, avoiding shock and lactic acidosis. In health, arterial hemoglobin is close to 
fully saturated so increasing VO2 relies mostly on increasing hemoglobin concentration, 
raising cardiac output, or by decreasing the oxygen binding affinity of hemoglobin 
(increasing the p50), such that more oxygen is available and released to the hypoxic 
tissues, as illustrated by the VO2 equation in Table 1.(21) Figure 3 illustrates the profound 
effect of p50 on VO2max, permitting the same VO2max to be achieved with a lower Hb if the 
p50 is higher. Similarly, this principle will allow the same VO2max to be achieved for a 
lower cardiac output, which may be of benefit for patients with limited cardiac reserve. The 
data in Figure 4 are the result of a mathematical model of postoperative anemia treated 
with sequential transfusions of low p50 PRBCs or high p50 PRBCs, similar to those 
depicted in Figure 2, using the ODCs from Figure 2 to calculate the AVO2diff (see Table 1 for 
derivation). As a patient’s anemia becomes more profound, they require greater cardiac 
output to maintain their baseline VO2. If we consider the pre-operative VO2, calculated for a 
cardiac output of 5L/min and a hemoglobin level of 14mg/dL, to be the baseline against 
which the post-transfusion models are compared, the figure shows the requisite cardiac 
output necessary to maintain the pre-op VO2. It is evident that the use of high p50 PRBCs 
creates a larger AVO2diff, which permits the CO component of VO2 to be lower while 
maintaining the pre-operative VO2. This represents an important reduction in 
compensatory cardiac demand required to maintain a given VO2, which offers benefit in 
patients with cardiac disease. Similarly, a patient could maintain the same VO2 with a lower 
hemoglobin level, potentially 
reducing the transfusion 
requirement, as illustrated in 
Figure 3. It is possible to 
manipulate the p50 of circulating 
blood or transfused blood, as 
outlined in the following sections. 
Section 3. Artificial Modulation of p50 
RSR-13/Efaproxiral 
Developed from the cholesterol lowering agents clofibrate and bezafibrate, structural 
analogs such as RSR-4 and RSR-13 demonstrated predictable p50 increases in a rat 
model.(22) Furthermore, it was shown that these fibrate analogs increased tissue 
oxygenation, thereby confirming the viability of increasing end-organ perfusion through 
changes in hemoglobin oxygen affinity.(23) RSR-13 improved post-injury mechanical 
function and ATP concentrations in isolated rat heart models of global myocardial ischemia 
and hyperkalemic arrest(24), and similar results were seen in dogs subjected to iatrogenic 
LAD occlusion(25) and hypothermic cardiopulmonary bypass,(26) suggesting potential 
benefits of increasing tissue oxygenation. 
While no increase in reactive oxygen species at the tissue level is seen after RSR-
13,(27) it was extensively studied as an adjunct to radiation therapy for patients with 
metastatic cancer to the brain, as there is evidence of an increase in brain tissue oxygen 
tension following RSR-13 administration.(28, 29). Phase I trials showed that RSR-13 
induced a dose-dependent increase in p50 in patients with glioblastoma multiforme (GBM) 
receiving radiation therapy.(30) Despite these encouraging early results, the follow-up 
Phase III study of 515 patients with brain metastases found a modest but insignificant 
increase in survival.(31) While this research demonstrated a proof-of-concept that 
increasing p50 could increase tissue oxygenation (in this case cancer cells), it did not 
translate into a clear survival benefit in brain cancer and was pursued no further. 
Inositol Polyphosphates (IHP, ITPP)  
 Shortly after the discovery of 2,3-DPG as an intracellular allosteric regulator of 
hemoglobin oxygen affinity(32), attention was turned to other organic phosphates that 
could influence hemoglobin oxygen binding. Inositol hexaphosphate (IHP) was known to 
produce a right-shift in avian hemoglobin(33), and it was shown to reproduce that effect in 
human blood.(34) However, the clinical feasibility of IHP use was limited by its inability to 
readily cross RBC membranes. Subsequent work led to the synthesis of inositol 
tripyrophosphate and myo-inositol trispyrophosphate (ITPP)(35), which are transported 
across the membrane of RBCs through an erythrocyte band-3 dependent mechanism.(36) 
Kieda and colleagues were the first to show the possible effects of p50 increases on the 
angiogenesis pathway, finding that human endothelial cells cultured under hypoxic 
conditions had significantly lower expression of HIF-1α, VEGF, and lower observed 
angiogenesis when exposed to ITPP-laden RBCs compared to standard human RBCs.(37) A 
subsequent study in chick ova noted a similar reduction in angiogenesis, and impaired 
growth of human glioma tissue when grafted onto the ovum as part of an experimental 
model.(38) Later work in rat models of hepatocellular(39) and pancreatic(40) carcinoma, 
as well as mouse models of primary(41) and metastatic(42) colorectal cancer, all showed 
decreases in angiogenesis pathway components, tumor size, and improved animal survival 
with ITPP alone or as an adjunct to chemotherapy. Currently, a Phase Ib/IIa trial is actively 
recruiting to test ITPP as an adjunct to standard-of-care chemotherapy in patients with 
non-resectable hepatopancreaticobiliary cancers,(43) although enthusiasm may be 
tempered by the failure of RSR-13 to improve outcomes despite promising, early 
observations. 
Hemodynamic and Systemic Effects of Modulating p50 in Model Systems 
 Several studies in model systems evaluated how modulation of hemoglobin p50 can 
influence cardiovascular system parameters and tissue oxygenation. An early study by 
Valeri and colleagues, who pioneered stored erythrocyte rejuvenation, looked at isolated 
canine hearts that were perfused by human RBCs containing either 80% or 300% of the 
normal 2,3-DPG concentration. The latter had a significantly higher p50, and produced 
significantly higher oxygen consumption by the myocardium at a standardized perfusion 
rate and, crucially, produce less lactate, confirming improved tissue oxygenation.(44) A 
similar study involving IHP-loaded erythrocytes in isolated rat hearts re-demonstrated the 
significant increase in oxygen consumption with high-p50 RBC, but further noted a 
significant decrease in coronary blood flow.(45) This latter point is particularly salient – 
the greater offloading of oxygen at the myocardium compensated for an overall decrease in 
perfusion, a concept that can be explained by considering the equation for calculating 
oxygen consumption (Table 1). 
Oxygen consumption (VO2) describes the amount of oxygen used in aerobic metabolism. If 
demand exceeds the maximum achievable VO2 (VO2max), the body switches to anaerobic 
metabolism, (46) with a resulting lactic acidosis that portends a poor prognosis in the 
critically ill. (47) Clinicians boost VO2, to avoid anaerobic metabolism and lactic acidosis, by 
using inotropic support to boost cardiac output, with potentially fatal arrhythmias, or by 
raising Hb, risking transfusion-associated complications. Increasing p50 and oxygen off-
loading in the tissues increases the SaO2 – SvO2 component in the VO2 equation and 
potentially offers a novel, third therapeutic option.  
 The first in vivo studies of p50 modulation were accomplished by Teisseire and 
colleagues using IHP-loaded erythrocytes in piglets. Following isovolumic exchange 
transfusion, piglets receiving high-p50 blood were noted to have an increased 
arteriovenous oxygen differential (AVO2diff), representing increased oxygen offloading. 
There was an observed negative correlation between p50 and cardiac output, but again the 
tissue oxygen consumption was maintained by the increase in end-organ oxygen 
release.(48) The same group then observed outcomes at later timepoints in another piglet 
cohort subjected to the same isovolumic exchange transfusion of high-p50 or normal-p50 
RBCs. IHP-loaded RBCs were noted to have a lifespan equivalent to that of normal porcine 
RBCs, and maintained their elevated p50 for over 20 days following transfusion, during 
which time interval the piglets maintained pre-transfusion oxygen consumption at 
significantly lower cardiac outputs.(49) A later pilot study looking at piglets placed on 
hypothermic cardiopulmonary bypass (CPB) primed with either high-p50 or normal-p50 
RBCs found that piglets receiving IHP-loaded erythrocytes had improved left ventricular 
and aortic pressures after CPB, as well as increased oxygen consumption, suggesting a 
potential cardioprotective use of high-p50 blood during CPB.(50) 
 Mouse model systems further explore the systemic effects of p50 modulation and 
potentially physiological benefit. Using donor blood from a mouse model expressing a 
mutant, low-affinity hemoglobin (Hb-Presbyterian), Huang and colleagues induced 
endotoxemia in wild-type mice and transfused them with either normal-affinity RBCs, low-
affinity RBCs, or saline. After 7 days, survival was significantly higher in the cohort 
receiving the low-affinity hemoglobin transfusion, and there was significantly lower 
hepatocyte apoptosis in this population,(51) suggesting benefit from increasing end-organ 
tissue oxygenation in this model of sepsis with organ dysfunction. In mouse models of 
heart failure, Watanabe and colleagues used coronary artery ligation to induce heart 
failure, after which they used one of two methods (bone marrow transplant from Hb-
Presbyterian mice or RSR-13 infusion) to increase p50. Compared to animals receiving 
control bone marrow or placebo, mice with high-p50 blood had significantly higher 
exercise capacity independent of any changes in cardiac function.(52) As such, the heart 
failure persisted (confirmed by histological evidence) but there was robust improvement in 
functional status. Similarly, in a transgenic mouse model of dilated cardiomyopathy, both 
intraperitoneal and oral ITPP resulted in dose-dependent and significant increases in 
maximal exercise capacity.(21) Cabrales et al. tested the physiologic effects of a 35% 
exchange transfusion in animal models using allosterically modified blood with a range of 
p50s, and found that the maximal tissue pO2 was produced by blood that had a slightly 
elevated p50.(53) 
Although formal human studies involving p50 modulation and exercise capacity 
have not yet been performed, both RSR-13 and ITPP have been listed as prohibited 
substances for professional athletes(54), given the potential for increases in systemic 
oxygen consumption and the functional advantages thereof. 
 
Section 4. p50 Modulation in Transfusion Medicine 
Red Blood Cell Storage and p50 
 Despite their status as the most commonly transfused blood product, packed red 
blood cell units (PRBCs) have been shown to undergo major deleterious changes while in 
storage. Amongst other changes,(55) after 7 days of refrigerated storage, the p50 is 
significantly reduced from a baseline of 27 to 22 then to a nadir of 18 mmHg after 21 days 
storage. (16) This is echoed in lowered 2,3 DPG levels in patients receiving allogeneic units 
rather than cell-saver blood during surgery, (56) and in older studies that observed 
reduced 2,3-DPG and p50 in a small cohort of adult patients who underwent cardiac 
surgery with CPB and received a mean of 18 units of stored blood.(57) This finding was 
reproduced in pediatric cardiac surgery patients, where it was noted that the age of 
transfused PRBCs correlated with the decrease in serum 2,3-DPG.(58) In this clinically 
relevant setting of acute transfusion, we can see that PRBCs will reduce p50, impairing O2 
off-loading in the tissues.. 
 How does this relate to recent large, prospective outcome studies comparing “fresh” 
to “old” blood? While studies in healthy volunteers(59) and anemic outpatients(60) have 
found no evidence of microcirculatory impairment with older stored units, there is 
evidence that subjects receiving autologous units have less boost in VO2max and exercise 
duration when receiving units stored for 42 days versus 7 days. (61) A small change in 
VO2max is a valid physiological outcome but may not translate into adverse clinical 
outcomes. The ABLE and RECESS trials addressed the question of RBC storage age in 
critically-ill and cardiac surgery populations, respectively. ABLE was powered to detect a 
difference in 90-day mortality between treatment groups, and found no significant 
difference in the same between the control (mean±SD blood age 22.0±8.4 days) and 
experimental (6.1±4.9 days) groups.(62) Similarly, RECESS found no difference between 
the control (mean±SD blood age 28.3±6.7 days) and experimental (7.8±4.8 days) groups’ 7-
day organ failure scores.(63) Similarly, the INFORM trial demonstrated no mortality 
differences between “old” (mean±SD 23.6±8.9 days, median 23, IQR 16-31) and “fresh” 
(mean±SD 13.0±7.6 days, median 11, IQR 8-16) blood.(64).Overall, the evidence does not 
convincingly argue for a change in transfusion practices on the basis of stored RBC age. 
However, the concept of p50 modulation as a transfusion intervention has not been 
formally tested by any of the aforementioned studies, because “fresh” blood had been 
stored for an average of 6 ± 5 days (ABLE), 8 ± 5 days (RECESS), or 13 ± 8 days (INFORM), 
and 2,3 DPG levels would already have been substantially reduced.  
RBC Rejuvenation 
 In the 1970s, Valeri and Zaroulis showed that there was a potential clinical benefit 
to be obtained from the use of a rejuvenation solution containing pyruvate, inosine, 
glucose, adenine, and phosphate. Outdated RBC units showed evidence of normalization of 
2,3-DPG, ATP, and p50 post-rejuvenation, and the authors demonstrated a significant 
increase in 24-hour post-transfusion recovery when using the rejuvenation process.(65) 
Other effects on the storage lesion, mostly from ATP restoration, include reduced osmotic 
and mechanical fragility(66), membrane lipid peroxidation(67), and injurious RBC-
endothelial interactions.(68) Nearly expired units could be rejuvenated and frozen, with 
acceptable 24-hour post-transfusion recovery and hemolysis measurements when thawed 
months to years later;(69-71) rejuvenation was primarily introduced and FDA approved to 
extend the storage life of rare phenotype RBC units.  
Figures 3 and 4 model the physiological benefits of high p50 blood in terms of 
maintaining VO2 at a lower cardiac output or at a lower Hb, with obvious potential 
applications. This could theoretically be achieved with rejuvenated blood that has a p50 of 
35-40mmHg. The logistics of achieving this in the clinical setting is under investigation.  
Expert Commentary 
 Oxygen consumption (VO2) describes the amount of oxygen used in aerobic 
metabolism. If demand exceeds the maximum achievable VO2 (VO2max), the body switches 
to anaerobic metabolism, with a resulting deleterious lactic acidosis. Clinicians boost VO2, 
to avoid anaerobic metabolism and lactic acidosis, by using inotropic support to boost 
cardiac output or by raising hemoglobin levels, risking arrhythmias and transfusion-
associated complications.  
 The formula for VO2 is a multiplication of hemoglobin level, cardiac output, and 
arteriovenous oxygen differential (SaO2-SvO2). Increasing p50 and oxygen off-loading in 
the tissues increases the SaO2 – SvO2 component in the VO2 equation and offers a 
therapeutic alternative to iatrogenic manipulation of CO and hemoglobin level. Current 
clinical studies are either focusing on increasing systemic p50 with the allosteric modifier 
myo-inositol trispyrophosphate (ITPP), to reduce tumor related angiogenesis, or using an 
FDA-approved solution of pyruvate, phosphate buffers, inosine, glucose and adenine, 
approved to extend the life of rare phenotype RBCs prior to frozen storage, to increase the 
p50 of RBCs prior to transfusion. 
5-year view 
 There is a peaking interest in a third therapeutic option for managing borderline 
shock states in critically ill patients especially when cardiac function is compromised or 
minimizing transfusion is desirable and adjuncts to cancer therapy have even broader 
appeal. Challenging existing transfusion triggers could result from using more efficacious 
RBC transfusions, with positive effects on inventory and donor exposure. Current studies 
evaluating increased p50 in the setting of chemotherapy(43) and sickle cell disease 
(NCT02731157) will inform emerging protocols, and using VO2max to test this concept of 
“blood transfusion efficacy” could be particularly applicable in this setting.(61) As a readily 
available parameter on a venous blood gas, increasing, or at least normalizing, p50 could 
feasibly become a goal of resuscitation. 
Key Issues 
 Cooperative binding in the 4 subunits of adult hemoglobin gives rise to the 
sigmoidal shape of the oxygen dissociation curve (ODC) and allows for the 
calculation of p50, the partial pressure of oxygen at which hemoglobin subunits are 
50% saturated. 
 Systemic oxygen consumption (VO2) is a function of cardiac output, blood 
hemoglobin levels, arterial and venous oxygen saturation, and p50. VO2 is increased 
by moderate elevations of p50 due to increased oxygen off-loading in the tissues. 
 Endogenous factors influence p50. Acidosis, 2,3-DPG and hypercapnia cause right-
shifting of the ODC, while alkalosis, hypothermia, methemoglobinemia, and fetal 
hemoglobinemia cause left shifting. 
 Increasing p50 in animal models has shown to improve systemic hemodynamics, 
tissue oxygenation, microvascular function, and exercise capacity. 
 Stored RBCs suffer a rapid depletion of 2,3-DPG, a resulting decrease in hemoglobin 
p50 and accumulate other biochemical/structural changes. 
 Commercially available processes to replete 2,3-DPG and ATP in stored RBCs, 
increase p50 and reverse some storage-related structural abnormalities.  
 Hemoglobin p50 demonstrates dose-dependent increases in vivo in response to 
inositol polyphosphates, exogenous 2,3 DPG and the fibrate analog efaproxiral. 
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